Recent developments of novel pharmacologic therapeutics for prevention of chemotherapy-induced peripheral neuropathy

Shuiying Hu, Kevin M. Huang, Elizabeth J. Adams, Charles L. Loprinzi, Maryam B. Lustberg

Research output: Contribution to journalReview articlepeer-review

15 Scopus citations

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is a common and dose-limiting toxicity, negatively affecting both quality of life and disease outcomes. To date, there is no proven preventative strategy for CIPN. Although multiple randomized trials have evaluated a variety of pharmacologic interventions for the treatment of CIPN, only duloxetine has shown clear efficacy in a phase III study. The National Cancer Institute's Symptom Management and Health-Related Quality of Life Steering Committee has identified CIPN as a priority for translational research in cancer care. Promising advances in preclinical research have identified several novel preventative and therapeutic targets, which have the potential to transform the care of patients with this debilitating neurotoxicity. Here, we provide an overarching view of emerging strategies and therapeutic targets that are currently being evaluated in CIPN.

Original languageEnglish (US)
Pages (from-to)6295-6301
Number of pages7
JournalClinical Cancer Research
Volume25
Issue number21
DOIs
StatePublished - 2019

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Recent developments of novel pharmacologic therapeutics for prevention of chemotherapy-induced peripheral neuropathy'. Together they form a unique fingerprint.

Cite this